(Q28743383)
Statements
A phase I randomized placebo controlled trial of the safety of 3% SPL7013 Gel (VivaGel®) in healthy young women administered twice daily for 14 days (English)
0 references
20 January 2011
0 references
6
0 references
1
0 references
e16258
0 references
20 January 2011
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference
1 reference